Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Regulus Therapeutics Inc. (NASDAQ:RGLS) has earned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $7.25.

A number of analysts recently issued reports on RGLS shares. Canaccord Genuity Group dropped their target price on shares of Regulus Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, March 19th. StockNews.com initiated coverage on shares of Regulus Therapeutics in a research note on Tuesday. They issued a “sell” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Regulus Therapeutics in a research report on Monday, March 25th. SVB Leerink initiated coverage on Regulus Therapeutics in a research report on Monday, March 18th. They issued an “outperform” rating and a $6.00 price objective on the stock. Finally, Wells Fargo & Company increased their target price on Regulus Therapeutics from $2.00 to $3.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 13th.

Regulus Therapeutics Stock Performance

RGLS stock opened at $2.22 on Friday. The business has a fifty day simple moving average of $2.12 and a 200-day simple moving average of $1.59. Regulus Therapeutics has a 52 week low of $1.08 and a 52 week high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.40) EPS for the quarter, hitting the consensus estimate of ($0.40). Research analysts expect that Regulus Therapeutics will post -0.52 EPS for the current year.

Institutional Investors Weigh In On Regulus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of RGLS. Federated Hermes Inc. bought a new stake in Regulus Therapeutics in the first quarter valued at about $8,656,000. Vanguard Group Inc. raised its position in shares of Regulus Therapeutics by 21.4% during the 1st quarter. Vanguard Group Inc. now owns 3,678,334 shares of the biopharmaceutical company’s stock valued at $1,096,000 after acquiring an additional 648,121 shares in the last quarter. FMR LLC lifted its stake in Regulus Therapeutics by 32.4% during the third quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock worth $4,033,000 after purchasing an additional 716,000 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in Regulus Therapeutics by 16.5% in the fourth quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock worth $348,000 after purchasing an additional 38,529 shares during the period. Finally, Exome Asset Management LLC bought a new stake in Regulus Therapeutics during the fourth quarter valued at $228,000. Institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.